To overcome this problem, the CRC survival is predicted based on selecting the differentially expressed genes (DEGs) in colorectal cancer that was based on the three-mutation status (KRAS, BRAF, and TP53) where they serve as a predictive biomarker of response to treatment in CRC. This evidence concerns the gene KRAS and colorectal carcinoma.